Breviane spiro-diterpenoid compound derived from deep-sea fungi as well as preparation method and application of Breviane spiro-diterpenoid compound
By extracting Breviane spirocyclic diterpenes from the deep-sea fungus Penicillium chrysogenum F59, combined with drug excipients, the side effects of existing anti-inflammatory drugs and the lack of effective anti-CoV drugs have been solved, and significant anti-inflammatory and anti-viral effects have been achieved. It provides a scientific basis for the development and utilization of deep-sea microbial resources.
Patent Information
- Application Number
- CN202411155292.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-22
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing anti-inflammatory drugs have side effects and lack effective anti-coronavirus drugs. Especially during the COVID-19 epidemic, it is urgent to develop low-toxic and highly effective drugs.
The complex structure of Breviane spirocyclic diterpenes are extracted from the deep-sea fungus Penicillium chrysogenum F59, and combined with drug excipients to form a pharmaceutical composition for the prevention or treatment of inflammation and novel coronavirus infection-related diseases.
Compounds 5 and 7 have significant anti-inflammatory activities, with IC50 values of 1.40 and 5.34 μM, respectively. Compounds 5 and 9 have significant inhibitory effects on SARS-CoV-2omicron subvariant BA.2 pseudovirus, with IC50 values of 8.47 and 10.25 μM, respectively, providing Candidate compounds for anti-inflammatory and anti-Coronavirus drugs.
Smart Images

Figure CN119039316A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of marine drugs, and specifically relates to Breviane spirocyclic diterpenoid compounds derived from deep-sea fungi and a preparation method and application thereof. Background Art
[0002] Inflammation is a basic pathological process with defense as the main factor in response to stimulation of various damaging factors in living tissues with vascular systems. It is a defensive response of the body to stimulation, often manifested as redness, swelling, heat, pain and dysfunction. Inflammation can occur in any part and tissue of the body, but excessive expression of inflammatory factors will directly affect the body's immune function. Inflammation effects lead to chronic obstructive pulmonary disease, chronic colitis and bacterial meningitis. Inflammation is promoted by macrophages to produce proinflammatory factors, including tumor necrosis factor (TNF-α), interleukins, prostaglandins, nitric oxide (NO) and reactive oxygen species. NO participates in many physiological and pathological processes of the body, participates in the cytotoxicity and immune regulation of macrophages, relaxes vascular smooth muscles, inhibits platelet aggregation and transmits nerve information, and also plays a complex role in inflammatory reactions. Excessive or insufficient NO plays an important role in many diseases. Currently, anti-inflammatory drugs used in clinical practice are generally divided into steroids and non-steroids, but there are corresponding side effects. Therefore, it is of great significance to develop highly effective and low-toxic anti-inflammatory drugs.
[0003] Novel coronavirus pneumonia (COVID-19) is a respiratory infectious disease caused by the new coronavirus (SARS-CoV-2). Its clinical symptoms mainly include fever, cough, shortness of breath and difficulty breathing. COVID-19 is the third highly pathogenic human coronavirus respiratory infectious disease after severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and has posed a huge threat to human life and health around the world. There is currently no safe and effective drug to treat the new coronavirus. Therefore, it is urgent to develop anti-new coronavirus drugs to protect human life and health.
[0004] Natural compounds have always been an important source of drug discovery due to their novel molecular structures and wide range of biological activities. According to research statistics, more than 60% of the 1,211 small molecule drugs approved for clinical use between 1981 and 2014 were derived from natural products and their derivatives. At present, the highly repetitive discovery of natural products has become a bottleneck in drug development, so people have gradually turned their attention to the ocean, which has been relatively less studied. The unique environment of the ocean (high salt, low temperature or local high temperature, high pressure, darkness and oligotrophy, etc.) makes the metabolic regulation pathways of marine organisms or microorganisms in it very different from those of terrestrial organisms or microorganisms, so some active secondary metabolites with novel structures can be produced, thereby providing model structures or lead compounds for the development of new drugs. Therefore, it is of great significance to find and discover natural products with anti-inflammatory and anti-new coronavirus activity from marine microorganisms, especially deep-sea microorganisms, for the development of corresponding therapeutic drugs. Summary of the invention
[0005] The present invention provides a novel Breviane spirocyclic diterpenoid compound with a complex structure. The compound is obtained by extracting from the deep-sea fungus Penicillium chrysogenum, preferably Penicillium chrysogenum F59, has anti-SARS-CoV-2omicron subvariant BA.2 pseudovirus activity, and can be used for the research and development of anti-new coronavirus drugs.
[0006] In one aspect, the present invention provides a Breviane spirocyclic diterpenoid compound having one of the following structures or its stereoisomers, tautomers, nitrogen oxides, solvates, metabolites, pharmaceutically acceptable salts, prodrugs or isotope labels:
[0007]
[0008] In another aspect, the present invention provides a pharmaceutical composition comprising the Breviane spirocyclic diterpenoid compound of the present invention and pharmaceutical excipients.
[0009] In some embodiments of the pharmaceutical composition, the pharmaceutical composition further comprises other active ingredients; the other active ingredients are traditional Chinese medicine ingredients and / or western medicine ingredients.
[0010] In some embodiments of the pharmaceutical composition, the western medicine ingredients include: at least one of apimod, R 82913, DS-6930, ONO 5334, oseltamivir phosphate, tetrandrine, clofazimine, astemizole, recombinant human angiotensin-converting enzyme 2 or favipiravir and / or their pharmaceutically acceptable salts.
[0011] On the other hand, the present invention also provides the use of the Breviane spirocyclic diterpenoid compound or its pharmaceutical composition in the preparation of a drug for preventing or treating inflammation or diseases related to novel coronavirus infection.
[0012] In some embodiments of use, the new coronavirus is a SARS-CoV-2omicron subvariant BA.2 pseudovirus.
[0013] In some embodiments of the use, in the pharmaceutical use for treating inflammation-related diseases, the compound or the compound contained in the pharmaceutical composition is compound 5 or a salt thereof, or compound 7 or a salt thereof;
[0014]
[0015] In some embodiments of the use, in the use of a drug for treating COVID-19-related diseases, the compound or the compound contained in the composition is compound 5 or a salt thereof, or compound 9 or a salt thereof;
[0016]
[0017] On the other hand, the present invention also provides a method for preparing and extracting the Breviane spirocyclic diterpenoid compound of the present invention, comprising:
[0018] (1) using an organic solvent to ultrasonically extract the fermentation product of deep-sea fungus Penicillium chrysogenum F59 to obtain an organic extract; the organic solvent is selected from one or more combinations of ethyl acetate, dichloromethane, n-butanol, acetone, and methanol;
[0019] (2) separating the organic extract in step (1) by normal phase silica gel column chromatography, using a dichloromethane-methanol gradient elution system with a volume ratio of 1:0 to 0:1; obtaining five fractions Fr.1, Fr.2, Fr.3, Fr4, and Fr5;
[0020] (3) passing the fraction Fr.3 obtained in step (2) through a reverse ODS silica gel column and eluting with a methanol / water gradient with a methanol ratio ranging from 75% to 100%, to obtain seven subfractions, namely, Fr.3-1, Fr.3-2, Fr.3-3, Fr.3-4, Fr.3-5, Fr.3-6, and Fr.3-7;
[0021] (4) passing the subfraction Fr.3-2 in step (3) through a normal phase silica gel column, using petroleum ether / ethyl acetate isocratic elution, volume ratio of 15:1; then separating and purifying by semi-preparative high pressure liquid chromatography, using acetonitrile / water, volume ratio of 32:68 as eluent, to prepare compounds 3 and 12;
[0022] (5) The subfraction Fr.3-6 in step (3) was subjected to normal phase silica gel column chromatography using isocratic elution with dichloromethane / methanol in a volume ratio of 50:1; and then separated and purified by semi-preparative high pressure liquid chromatography using acetonitrile / water in a volume ratio of 45:55 as the eluent to prepare compound 11;
[0023] (6) The fraction Fr.4 obtained in step (2) was subjected to normal phase silica gel column chromatography, eluted isocratically with dichloromethane / methanol, with a volume ratio of 100:1, to obtain five sub-fractions, Fr.4-1, Fr.4-2, Fr.4-3, Fr.4-4, and Fr.4-5;
[0024] (7) The subfraction Fr.4-1 in step (6) was separated and purified by isocratic elution with petroleum ether / ethyl acetate on a normal phase silica gel column, with a volume ratio of 10:1, and semi-preparative high pressure liquid chromatography, with an eluent of acetonitrile / water, with a volume ratio of 33:67, to obtain compound 1;
[0025] (8) The subfraction Fr.4-2 in step (6) was subjected to Sephadex LH-20 gel column chromatography, eluted with methanol, and then separated and purified by semi-preparative high pressure liquid chromatography to prepare compound 5, compound 8, and compound 10;
[0026] (9) The subfraction Fr.4-3 in step (6) was separated and purified by isocratic elution with dichloromethane / methanol (volume ratio: 50:1) on a normal phase silica gel column and semi-preparative high pressure liquid chromatography (eluent: acetonitrile / water (volume ratio: 33:67) to obtain compounds 7 and 13;
[0027] (10) The subfraction Fr.4-4 in step (6) was separated and purified by isocratic elution with dichloromethane / methanol (volume ratio 40:1) on a normal phase silica gel column and semi-preparative high pressure liquid chromatography (eluent acetonitrile / water (volume ratio 40:60) to obtain compounds 4 and 9;
[0028] (11) The subfraction Fr.4-5 in step (6) was separated and purified by isocratic elution with dichloromethane / methanol in a normal phase silica gel column, with a volume ratio of 30:1, and semi-preparative high pressure liquid chromatography, with acetonitrile / water in a volume ratio of 45:55 as the eluent, to obtain compounds 2 and 6.
[0029] In some embodiments of the preparation method, the fermentation method of the deep-sea fungus Penicillium chrysogenum F59 fermentation product comprises:
[0030] (1) Deep-sea fungus Penicillium chrysogenum F59 was transferred to sterilized PDB medium and cultured in a shaker to obtain the seed fermentation liquid of the fungus;
[0031] (2) The prepared seed culture solution is inoculated into a rice solid culture medium and placed in a constant temperature chamber at 20-30° C. for static fermentation culture for 25-35 days.
[0032] Terminology
[0033] Certain embodiments of the present invention are now described in detail. The present invention is intended to cover all substitutions, modifications and equivalent technical solutions, which are all included in the scope of the present invention as defined in the claims. It should be appreciated by those skilled in the art that many methods and materials similar or equivalent to those described herein can be used to practice the present invention. The present invention is by no means limited to the methods and materials described herein. In the event that one or more of the combined documents, patents and similar materials are different from or contradictory to the present application (including but not limited to defined terms, term applications, described technologies, etc.), the present application shall prevail.
[0034] It should be further appreciated that certain features of the invention, which for clarity are described in multiple separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which for brevity are described in a single embodiment, may also be provided separately or in any suitable sub-combination.
[0035] Unless otherwise specified, all technical terms used in the present invention have the same meaning as commonly understood by those skilled in the art to which the present invention belongs. All patents and publications related to the present invention are incorporated herein by reference in their entirety.
[0036] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.
[0037] In the following, all numbers disclosed herein are approximate, regardless of whether the words "about" or "approximately" are used. The value of each number may vary by 1%, 2%, 5%, 7%, 8%, 10%, 15% or 20%. Whenever a number having a value of N is disclosed, any number having a value of N+ / -1%, N+ / -2%, N+ / -3%, N+ / -5%, N+ / -7%, N+ / -8%, N+ / -10%, N+ / -15% or N+ / -20% is explicitly disclosed, where "+ / -" means plus or minus.
[0038] The term "comprising" is an open expression, that is, including the contents specified in the present invention but not excluding other contents.
[0039] When substituents are described by conventional chemical formulas written from left to right, the substituents also include chemically equivalent substituents that would result if the formula were written from right to left. For example, -CH2O- is equivalent to -OCH2-.
[0040] The term "tautomer" or "tautomeric form" refers to structural isomers with different energies that can be mutually converted through a low energy barrier. If tautomerism is possible (such as in solution), a chemical equilibrium of tautomers can be reached. For example, proton tautomers (protontautomers) (also known as prototropic tautomers) include mutual conversions by proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include mutual conversions by the reorganization of some bonding electrons. A specific example of keto-enol tautomerism is the interconversion of pentane-2,4-dione and 4-hydroxypent-3-ene-2-one tautomers. Another example of tautomerism is phenol-keto tautomerism. A specific example of phenol-keto tautomerism is the interconversion of pyridine-4-ol and pyridine-4 (1H)-one tautomers. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
[0041] The term "stereoisomers" refers to compounds that have identical chemical constitution, but differ in the way the atoms or groups are arranged in space. Stereoisomers include enantiomers, diastereomers, conformational isomers (rotamers), geometric isomers (cis / trans isomers), atropisomers, and the like.
[0042] The term "nitrogen oxide" refers to when a compound contains several amine functional groups, one or more nitrogen atoms can be oxidized to form an N-oxide. A special example of an N-oxide is an N-oxide of a tertiary amine or an N-oxide of a nitrogen-containing heterocyclic nitrogen atom. The corresponding amine can be treated with an oxidizing agent such as hydrogen peroxide or a peracid (e.g., peroxycarboxylic acid) to form an N-oxide (see Advanced Organic Chemistry, Wiley Interscience, 4th edition, Jerry March, pages). In particular, N-oxides can be prepared by the method of LW Deady (Syn. Comm. 1977, 7, 509-514), wherein, for example, in an inert solvent such as dichloromethane, an amine compound is reacted with meta-chloroperbenzoic acid (MCPBA).
[0043] The term "metabolite" refers to a product obtained by the metabolism of a specific compound or its salt in vivo. The metabolite of a compound can be identified by techniques known in the art, and its activity can be characterized by experimental methods as described in the present invention. Such products can be obtained by administering the compound through oxidation, reduction, hydrolysis, amidation, deamidation, esterification, defatting, enzymatic cleavage, etc. Accordingly, the present invention includes metabolites of compounds, including metabolites produced by contacting the compounds of the present invention with mammals for a period of time.
[0044] The term "pharmaceutically acceptable salt" refers to organic and inorganic salts of the compounds of the present invention. Pharmaceutically acceptable salts are well known in the art, as described in the literature: SM Berge et al., J. Pharmaceutical Sciences, 66: 1-19, 1977. Pharmaceutically acceptable salts include salts formed by compounds with acids, including but not limited to inorganic acid salts (such as hydrochlorides, hydrobromides, phosphates, sulfates, nitrates, perchlorates) and organic acid salts (such as acetates, glycolates, oxalates, maleates, tartrates, citrates, succinates, fumarates, mandelates, sulfosalicylate), or other methods described in books and literature, such as ion exchange methods, to obtain these salts. More pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, cyclopentylpropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oleate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, stearate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Pharmaceutically acceptable salts also include salts of compounds formed with bases, including, but not limited to, inorganic base salts (such as alkali metal salts, alkaline earth metal salts, ammonium salts and N+(C 1-4 The present invention also contemplates quaternary ammonium salts formed by any compound containing N groups. Water-soluble or oil-soluble or dispersible products can be obtained by quaternization. Pharmaceutically acceptable salts further include appropriate, non-toxic ammonium, quaternary ammonium salts and amine cations formed by counter-balancing ions, such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, C1-8 sulfonates and aromatic sulfonates. Organic base salts (such as primary amine salts, secondary amine salts and tertiary amine salts, substituted amines (including naturally occurring substituted amines, cyclic amines, basic ion exchange resins) salts), certain organic amine salts include, for example, isopropylamine salts, benzathine salts, choline salts, diethanolamine salts, diethylamine salts, lysine salts, meglumine salts, piperazine salts and tromethamine salts.
[0045] The term "solvate" refers to an association formed by one or more solvent molecules and the compound of the present invention. The solvent can be water, acetic acid, ether, isopropyl ether, petroleum ether, ethyl formate, ethyl acetate, isopropyl acetate, n-propyl acetate, isobutyl acetate, n-butyl acetate, methyl tert-butyl ether (MTBE), n-heptane, a mixed solvent of ethanol and water in a volume ratio of 10:90 to 90:10, acetone, methyl isobutyl ketone, acetonitrile, benzene, chloroform, carbon tetrachloride, dichloromethane, dimethyl sulfoxide, 1,4-dioxane, ethanol, ethyl acetate, ethylene glycol, n-butanol, tert-butanol , sec-butyl alcohol, N,N-dimethylacetamide, N,N-dimethylformamide, formamide, formic acid, n-hexane, cyclohexane, n-heptane, a mixed solvent of n-heptane and ethyl acetate in a volume ratio of 1:5 to 5:1, isopropanol, methanol, butanone, l-methyl-2-pyrrolidone, mesitylene, nitromethane, polyethylene glycol, n-propanol, isopropanol, 2-acetone, 4-methyl-2-pentanone, pyridine, tetrahydrofuran, methyl ethyl ketone, toluene, xylene, isopropylbenzene or a mixture thereof, etc.
[0046] The term "isotopically labeled" means that the compounds of the present invention are labeled with an isotope. They are identical to those described herein except for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Exemplary isotopes that may also be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 16 Oh, 17 Oh, 31 P, 32 P, 36 S, 18 F and 37 Cl.
[0047] The term "prodrug" as used in the present invention refers to a compound that is converted into the compound 1 or 2 of the present invention in vivo. Such conversion is affected by the hydrolysis of the prodrug in the blood or the conversion of the prodrug into the parent structure by enzymes in the blood or tissues. The prodrug compound of the present invention can be an ester. In the present invention, the esters that can be used as prodrugs include phenyl esters, aliphatic (C 1-24) esters, acyloxymethyl esters, carbonates, carbamates and amino acid esters. For example, a compound of the present invention contains a hydroxyl group, which can be acylated to obtain a compound in the form of a prodrug. Other prodrug forms include phosphate esters, such as these phosphate ester compounds obtained by phosphorylation of the hydroxyl group on the parent. For a complete discussion of prodrugs, please refer to the following documents: Higuchi et al., Pro-drugs as Novel Delivery Systems, Vol. 14, ACSSymposium Series; Roche et al., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987; Rautio et al., Prodrugs: Design and Clinical Applications, Nature Reviews Drug Discovery, 2008, 7, 255-270, and Hecker et al., Prodrugs of Phosphates and Phosphonates, J. Med. Chem., 2008, 51, 2328-2345.
[0048] The deep-sea fungus Penicillium chrysogenum F59 of the present invention is deposited in the China Marine Microbiological Culture Collection Center, with the culture collection number: MCCC 3A00317. It can be shared through the culture collection number and can be obtained from the website: https: / / www.mccc.org.cn / BacteriaService / Service1
[0049] Advantages of the present invention:
[0050] The present invention provides a novel Breviane spirocyclic diterpenoid compound prepared from the fermentation product of deep-sea fungus Penicillium chrysogenum F59. The extraction and separation process is simple, and the raw materials can be obtained by repeated fermentation, which has the advantage of resource renewable. Some spirocyclic diterpenoid compounds have significant anti-inflammatory and anti-new coronavirus activities. Among them, compounds 5 and 7 have significant anti-inflammatory activity, and their IC 50 The values were 1.40 and 5.34 μM, respectively. Compounds 5 and 9 have significant anti-new coronavirus activity, and their IC 50 The values were 8.47 and 10.25 μM, respectively. The present invention provides candidate compounds for the development of anti-inflammatory and anti-new coronavirus drugs, and promotes the development and utilization of deep-sea microbial resources. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] Figure 1 COSY, HMBC, and NOESY correlations of compound 1.
[0052] Figure 2 The measured ECD spectrum of compound 1 in MeOH and the calculated ECD spectrum at the B3LYP / 6-311G (2d, p) level.
[0053] Figure 3 COSY, HMBC, and NOESY correlations of compound 2.
[0054] Figure 4 COSY, HMBC, and NOESY correlations of compound 8.
[0055] Figure 5 COSY, HMBC, and NOESY correlations of compound 9. DETAILED DESCRIPTION
[0056] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with embodiments. The specific embodiments described herein are only used to explain the present invention and are not intended to constitute any limitation of the present invention. In addition, in the following description, the description of known structures and technologies is omitted to avoid unnecessary confusion of the concepts of the present disclosure. Such structures and technologies are also described in many publications.
[0057] The reagents used in the present invention can be purchased from the market or prepared by the method described in the present invention.
[0058] Example 1: Preparation and structural identification of Breviane spirocyclic diterpenoid compounds involved in the present invention
[0059] 1. Preparation of Breviane Spirocyclic Diterpenoids
[0060] (1) Preparation of seed fermentation liquid: Deep-sea fungus Penicillium chrysogenum F59 was inoculated into PDA solid medium and then cultured in an incubator at 25°C for 2 days. 100 mL of PDB medium was added to each 250 mL Erlenmeyer flask. After high-pressure steam sterilization, spores and mycelium were inoculated into PDB liquid medium and placed in a shaker (200 rpm, 28°C) for 3 days to prepare seed fermentation liquid.
[0061] (2) Large-scale fermentation and extraction of fermentation products: Rice culture medium was used to expand the scale of fermentation. 100 g of rice, 4.9 g of sea salt, and 150 mL of tap water were added to 50 1L triangular flasks. After the rice culture medium was sterilized at 121°C for 30 min, 3 mL of seed fermentation liquid was added to each bottle, and then placed in a constant temperature room at 25°C for static fermentation for 30 days. After the fermentation was completed, ethyl acetate organic solvent was added and the solid culture medium was crushed. After ultrasonic extraction, 38 g of ethyl acetate fermentation extract was obtained.
[0062] (3) The ethyl acetate fermentation extract obtained in step (2) was subjected to normal phase silica gel chromatography using a dichloromethane / methanol (1:0-0:1, v / v) gradient elution, and five fractions (Fr.1 to Fr.5) were obtained after TLC analysis and merging.
[0063] (4) The fraction Fr.3 obtained in step (3) was passed through a reverse ODS silica gel column and gradient eluted with methanol / water (75% to 100%, v / v) to obtain 7 sub-fractions (Fr.3-1 to Fr.3-7). Among them, sub-fraction Fr.3-2 was subjected to normal phase silica gel column chromatography and isocratically eluted with petroleum ether / ethyl acetate (15:1, v / v); then, compound 3 (11.3 mg) and compound 12 (2.5 mg) were prepared by semi-preparative high pressure liquid chromatography (acetonitrile / water elution, 32:68, v / v).
[0064] (5) The subfraction Fr.3-2 obtained in step (4) was subjected to normal phase silica gel column chromatography using isocratic elution with dichloromethane / methanol (50:1, v / v); and then subjected to semi-preparative high pressure liquid chromatography (acetonitrile / water elution, 45:55, v / v) to obtain compound 11 (2.6 mg).
[0065] (6) The fraction Fr.4 obtained in step (3) was subjected to normal phase silica gel column chromatography and isocratically eluted with dichloromethane / methanol (100:1, v / v) to obtain 5 subfractions (Fr.4-1 to Fr.4-5). Among them, subfraction Fr.4-1 was subjected to normal phase silica gel column (isocratically eluted with petroleum ether / ethyl acetate, 10:1, v / v) and semi-preparative high pressure liquid chromatography (eluted with acetonitrile / water, 33:67, v / v) to prepare compound 1 (5.6 mg).
[0066] (7) Fr.4-2 obtained in step (6) was subjected to Sephadex LH-20 gel column chromatography and eluted with a methanol system to obtain three sub-fractions (Fr.4-2-1 to Fr.4-2-3). Among them, sub-fraction Fr.4-2-1 was subjected to semi-preparative high pressure liquid chromatography using acetonitrile / water (37:63, v / v) as the mobile phase to obtain compound 8 (3.9 mg). Sub-fraction Fr.4-2-2 was subjected to semi-preparative high pressure liquid chromatography using acetonitrile / water (40:60, v / v) as the mobile phase to obtain compound 5 (1.9 mg). Sub-fraction Fr.4-2-3 was subjected to semi-preparative high pressure liquid chromatography using acetonitrile / water (34:66, v / v) as the mobile phase to obtain compounds 8 (3.9 mg) and 10 (6.1 mg).
[0067] (8) Fr.4-3 obtained in step (6) was purified by normal phase silica gel column (dichloromethane / methanol, 50:1, v / v) and semi-preparative high pressure liquid chromatography (acetonitrile / water, 33:67, v / v) to obtain compounds 7 (23.5 mg) and 13 (2.6 mg).
[0068] (9) Fr.4-4 obtained in step (6) was purified by normal phase silica gel column (dichloromethane / methanol, 40:1, v / v) and semi-preparative high pressure liquid chromatography (acetonitrile / water, 40:60, v / v) to obtain compounds 4 (2.5 mg) and 9 (1.6 mg).
[0069] (10) The subfraction Fr.4-5 obtained in step (6) was purified by normal phase silica gel column (dichloromethane / methanol, 30:1, v / v) and semi-preparative high pressure liquid chromatography (acetonitrile / water, 45:55, v / v) to obtain compounds 2 (0.6 mg) and 6 (2.5 mg). 2. Structural identification of new structure mixed terpenoid compounds
[0070] Compound 1 is a white powder. According to HR-ESI-MS (m / z 473.1927[M+Na] + ), combined with NMR data, the molecular formula of compound 1 is C 27 H 30 O6, the molecular unsaturation is 13. 1 H NMR and HSQC spectra show that there are five methyl signals (H3-16, H3-19, H3-20, H3-6ˊ, H3-7ˊ), four methylene signals (H2-2, H2-6, H2-7, H2-17), and seven methine signals (H-1, H-18, H-5, H-9, H-11, H-12, H-15). 13C NMR shows 27 carbon signals, including five methyl groups, four methylene groups, seven methine groups, and eleven non-protonated carbons. The above NMR data show that there are four CC double bonds and two carbonyl groups occupying six unsaturations, indicating that compound 1 is a seven-ring molecular skeleton structure. According to HMBC and 1 H- 1 The COSY correlation of H-1 to H2-2 in the H COSY spectrum, the HMBC correlation of H2-2 to C-3 and C-18, H3-19 to C-4, C-5 and C-18, and H3-20 to C-10, C-5 and C-1, constructed the structure of ring A. The COSY correlation of H-5 to H2-6 and H2-7, H-12 to H-11 and H-6, the HMBC correlation of H3-20 to C-10, C-5 and C-9, H2-17 to C-8, C-7 and C-14, and H3-16 to C-13, C-12 and C-14 constructed the decalin structure of ring B and ring C ( Figure 1 ), and connected to the A ring through C-5 and C-10, H-15 to C-14, HMBC correlation of C-2ˊ and C-3ˊ and C-14(δ C 103.1) confirmed that the D ring is a tetrahydrofuran ring connected to the C ring through C-14. The HMBC correlations of H3-7ˊ to C-3ˊ, C-4ˊ and C-5ˊ, and H3-6ˊ to C-4ˊ and C-5ˊ were combined with C-5ˊ (δ C 164.0) and C-1ˊ(δ C 162.4) confirmed that the E ring is an α-pyrone connected to the D ring via C-3ˊ and C-2ˊ. The HMBC correlation from H-11 to C-1 and the C-1 (δ C 85.6) and C-11 (δ C 72.2) indicates that C-1 and C-11 are connected to the same O to form an ether bond. Similarly, C-15 (δ C 84.4) and C-17(δ C 69.9), an ether bond is also formed between them, which finally determines the planar structure of compound 1.
[0071] The correlation of H-1 with H3-20, H-11 with H3-20, H2-17 with H3-20, and H2-17 with H-15 in the NOESY spectrum indicates that these protons are on the same face of the ring, while the correlation of H-5 with H-9 indicates that these protons are on opposite planes ( Figure 1), the relative configuration of compound 1 was determined to be 1S*, 5S*, 8R*, 9R*, 10R*, 11R*, 14S*, 15S*. Combining the ECD data calculated by quantum chemistry, it was found that the measured ECD spectrum was consistent with the ECD data of the calculated spectrum of 1a (1S, 5S, 8R, 9R, 10R, 11R, 14S, 15S)-1 ( Figure 2 ), and finally determined the absolute configuration of compound 1 to be 1S, 5S, 8R, 9R, 10R, 11R, 14S, 15S.
[0072] Compound 2 is a light pink solid. According to HR-ESI-MS (m / z 473.1928 [M+Na] + ), combined with NMR data, the molecular formula of compound 2 is C 27 H 30 O6, unsaturation is 13. 1 HNMR, 13 C NMR and HSQC spectra show six methyl groups, two methylene groups, seven methine groups (including four olefins and one oxygen-containing group), and twelve unprotonated carbons (including three carbonyl groups and six olefins). Its NMR data are similar to those of the known compound Brevione F, except that the C-11 position (δ C 198.4) is a keto group rather than a hydroxyl unit, and the C-15 position (δ C 74.1) has an additional hydroxyl group. H-12 to C-11 HMBC correlation, OH-15 to H-15 COSY correlation and C-11 (δ C 198.4) and C-15 (δ C 74.1) confirmed this speculation and confirmed the planar structure of 2 ( Figure 3 ). NOESY correlation of H3-20 with H3-17α shows that these protons are on the same face of the ring, while NOESY correlation of H-5 with H-9 and H3-17β with OH-15 shows that they are on opposite faces of the ring ( Figure 3 ). Therefore, the relative configuration of compound 2 was determined to be 5S*, 8R*, 9R*, 10R*, 14S*, 15S*. Based on the experimental ECD data and the biogenic synthesis pathway, the absolute configuration of the compound was inferred to be 5S, 8R, 9R, 10R, 14S, 15S.
[0073] Compound 3 was a light yellow solid. According to HR-ESI-MS (m / z 475.2084 [M+Na] + ), combined with NMR data, it is known that the molecular formula of compound 3 is C 27 H 32 O6, the molecular unsaturation is 12. 1 HNMR, 13C NMR and HSQC spectra show six methyl groups, three methylene groups, seven methine groups (including two olefins and three oxygen groups), and eleven non-protonated carbon groups (including two carbonyl groups and six olefins). Its NMR data are similar to those of the known compound Breviones P, except that the C-15 position (δ C 73.3) has one more hydroxyl unit. COSY correlation of OH-15 and H-15 and C-15 (δ C 73.3) confirmed this speculation and determined the planar structure of compound 3. The correlation of H3-20 with H3-17α, H3-20 with H-1, and H3-20 with H-11 in the NOESY spectrum showed that these protons were in the same plane of the ring, and the correlation of H-5 with H-9 and H3-17β with OH-15 showed that these protons were in opposite planes. The configuration of compound 3 was determined to be 1S, 5S, 8R, 9R, 10S, 11R, 14S, 15S.
[0074] Compound 4 was a white solid. According to HR-ESI-MS (m / z 489.2240 [M+Na] + ), combined with NMR data, we know that the molecular formula of compound 4 is C 28 H 34 O6, the molecular unsaturation is 12. 1 HNMR, 13 C NMR and HSQC spectra show six methyl groups, one methoxy group, three methylene groups, seven methine groups (including two olefins and three oxygen groups), and eleven non-protonated carbon groups (including two carbonyl groups and six olefins). Its NMR data are very similar to those of compound 3, except that the C-15 position (δ C 83.1) is a methoxy group rather than a hydroxyl group. The HMBC correlation of H-15 to OMe-15 confirmed this speculation and determined the planar structure of compound 4. The correlation of H3-20 with H3-17α, H3-20 with H-1, and H3-20 with H-11 by NOESY spectrum showed that these protons were all in the same plane of the ring, and the correlation of H-5 with H-9 and H3-17β with OMe-15 showed that these protons were in the opposite plane of the ring. The absolute configuration of compound 4 was determined to be 1S, 5S, 8R, 9R, 10S, 11R, 14S, 15S based on ECD and biogenic pathway.
[0075] Compound 5 was a white solid. According to HR-ESI-MS (m / z 471.1770 [M+Na] + ) and NMR data indicate that the molecular formula of compound 5 is C 27 H 28 O6, unsaturation is 14. 1 HNMR, 13The C NMR and HSQC spectra show five methyl groups, two methylene groups, nine methine groups (including four olefins and three oxygen-containing groups), and eleven non-protonated carbon groups (including two carbonyl groups and six olefins). Its NMR data are similar to those of compound 1, but in the NMR data of compound 5, COSY correlations of H2-1 and H2-2, HMBC correlations of H-11 to C-17, and C-1 (δ C 154.5), C-2(δ C 127.0) and C-17 (δ C 108.1). This result indicates that C-1 forms a CC double bond with C-2, C-11 and C-17 are connected to the same oxygen and form a tetrahydrofuran ring with C-9 and C-8, and the planar structure of compound 5 is determined. NOESY spectrum H2-7α is related to H-17, H3-20 to H-17, and H3-20 to H-11, indicating that these protons are in the same plane, and H-5 and H-9 indicate that these protons are in opposite planes. Therefore, the absolute configuration of compound 5 is 5S, 8S, 9R, 10S, 11S, 14S, 15S, 17S.
[0076] Compound 6 was a white solid. According to HR-ESI-MS (m / z 473.1927 [M+Na] + ) Combined with NMR data, the molecular formula of compound 6 was determined to be C 27 H 30 O6, unsaturation is 13. 1 HNMR, 13 The C NMR and HSQC spectra show five methyl groups, three methylene groups, eight methine groups (including four olefins and two oxygen groups), and eleven non-protonated carbon groups (including two carbonyl groups and six olefins). Its NMR data are similar to those of the known compound Brevione H, but 1 H- 1 In the H COSY spectrum, H2-1 was observed to be correlated with H2-2, and H-12, H2-11 and H-9, indicating that C-1(δ C 153.9) and C-2(δ C 129.0) formed a CC double bond, C-11 (δ C 24.1) is a methylene group, which confirms the planar structure of compound 6. Through NOESY spectrum, H3-20 is related to H-17, indicating that these protons are in the same plane, and H-5 is related to H-9, indicating that these protons are in opposite planes. Finally, the absolute configuration of compound 6 was determined to be 5S, 8S, 9R, 10S, 14S, 15S, 17R.
[0077] Compound 7 was a light yellow solid. According to HR-ESI-MS (m / z 475.2081 [M+Na]+ ), combined with NMR data, the molecular formula of compound 7 was determined to be C 27 H 32 O6, unsaturation is 12. 1 HNMR, 13 C NMR and HSQC spectra show six methyl groups, three methylene groups, seven methine groups (including three olefins and two oxygen-containing groups), and eleven non-protonated carbons (including two carbonyl groups and five olefins). Its NMR data showed the presence of two carbonyl groups and four olefins occupying six degrees of unsaturation, confirming that it has a seven-ring skeleton structure and is similar to the known compound Brevione F. In HMBC and 1 H- 1 In the H COSY spectrum, HMBC correlations from H3-16 to C-13 and C-12 and COSY correlations from H-12 to H-11 were observed, indicating that C-12 (δ C 63.6) and C-13 (δ C 61.4) connected with the same oxygen to form an ethylene oxide part, and the planar structure of compound 7 was determined. Through NOESY spectrum, the correlation between H3-20 and H3-17, OH-11 and H3-17, and H-12 and H3-17 indicated that these protons were in the same plane, and the correlation between H-5 and H-9 indicated that these protons were in opposite planes. According to ECD data and biogenic pathway, the absolute configuration of compound 7 was determined to be 5S, 8R, 9R, 10R, 11R, 12S, 13R, 14R.
[0078] Compound 8 was a light yellow solid. According to HR-ESI-MS (m / z 463.208, [M+Na] + ), combined with NMR data, the molecular formula of compound 8 was determined to be C 26 H 32 O6, unsaturation is 11. 1 HNMR, 13 C NMR and HSQC spectra show five methyl groups, four methylene groups, eight methine groups (including two olefins and four oxygen groups) and nine non-protonated carbon groups (including two carbonyl groups and four olefins). Its NMR data are very similar to those of Brevione E, indicating that 8 may be the cis-trans isomer of Brevione E. The observation of H3-7ˊ and H2-2ˊ correlation in the NOESY spectrum confirms this speculation and determines the planar structure of ( Figure 4 ). In addition, the experimental ECD data of compound 8 are very similar to those of Brevione E, and its absolute configurations are speculated to be 1S, 5S, 8S, 9R, 10S, 11R, 14S, 15S, and 17R, respectively.
[0079] Compound 9 was a white solid. According to HR-ESI-MS (m / z 459.2132 [M+Na] + ), combined with NMR data, the molecular formula of compound 9 was determined to be C 27 H 32 O5, the molecular unsaturation is 12. 1 HNMR, 13 C NMR and HSQC spectra show seven methyl groups, three methylene groups, five methine groups (including three olefins), and twelve unprotonated carbon groups (including three carbonyl groups and five olefins), of which four CC double bonds and three carbonyl groups occupy seven unsaturations, indicating that 9 is a five-ring skeleton structure. 1 H- 1 The structure of ring A was constructed by COSY correlation of H2-1 to H2-2 in the HCOSY spectrum, HMBC correlation of H2-2 to C-3 and C-4, H3-18 to C-3 and C-4, H3-19 to C-4 and C-5, and H3-20 to C-10, C-5 and C-1. Figure 5 The COSY correlations of H-5 to H2-6 and H2-7, the HMBC correlations of H3-20 to C-10, C-5 and C-9, H3-17 to C-8, C-7, C-9 and C-14, H-12 to C-11 and C-9, and H3-16 to C-13, C-12 and C-14 constructed the decalin moieties of ring B and ring C, and connected ring A through C-5 and C-10, and the HMBC correlations of H2-15 to C-14, C-2ˊ and C-3ˊ and C-14 (δ C 97.3) confirmed that the D ring is a tetrahydrofuran ring connected to the C ring through C-14. The HMBC correlations of H3-7ˊ to C-3ˊ, C-4ˊ and C-5ˊ, and H3-6ˊ to C-4ˊ and C-5ˊ were combined with C-5ˊ (δ C 161.6) and C-1ˊ(δ C The obvious downfield shift of 160.5) confirmed that the E ring was an α-pyrone connected to the D ring through C-3ˊ and C-2ˊ, confirming the planar structure of compound 9.
[0080] By correlating H3-20 with H3-17 in the NOESY spectrum, it was determined that these protons were in the same plane, and by correlating H-5 with H-9, it was determined that these protons were in opposite planes ( Figure 5 ), the relative configuration of compound 9 was determined to be 5R*, 8R*, 9R*, 10S*, 14S*. The absolute configuration was determined by combining the ECD data calculated by quantum chemistry, and it was found that the measured ECD spectrum was consistent with the calculated spectrum (5R, 8R, 9R, 10S, 14S)-9(9a), thus determining the absolute configuration of compound 9 to be 5R, 8R, 9R, 10S, 14S.
[0081] Compound 10 was a white needle-like solid. According to HR-ESI-MS (m / z 461.2287, [M+Na] + ), combined with NMR data, the molecular formula of compound 10 was determined to be C 27 H 34 O5, the molecular unsaturation is 11. 1 H NMR, 13 C NMR and HSQC spectra show six methyl groups, five methylene groups, five methine groups (including three olefins), and eleven non-protonated carbon groups (including two carbonyl groups and five olefins). Its NMR data are similar to those of compound 9, except that C-19 (δ C 67.1) has one more hydroxyl unit, C-11 (δ C 22.7) is a methylene group rather than a ketone. COSY correlations of OH-19 with H2-19 and H-12, H2-11 with H-9 confirmed this view and determined the planar structure of 10. NOESY correlations of H3-18 with H3-20, H3-20 with H3-17 indicated that these protons were in the same plane, and correlations of H-5 with H-9 indicated that these protons were in opposite planes. Based on ECD data and biogenic pathways, the absolute configuration of compound 10 was determined to be 5R, 8R, 9R, 10S, 14S.
[0082] Compound 11 was a light yellow solid. According to HR-ESI-MS (m / z 479.2395 [M+Na] + ) and NMR data confirmed that the molecular formula of compound 11 is C 27 H 36 O6, unsaturation is 10. 1 H NMR, 13 The C NMR and HSQC spectra showed seven methyl groups, four methylene groups, five methine groups (including one olefin and two oxygen-containing groups) and eleven non-protonated carbon groups (including two carbonyl groups and five olefins). The NMR data were similar to those of compound 9. COSY correlations between H2-1 and H-1 and H-12, and between H-11 and H-9 were observed in the NMR data, indicating that the CC double bond between C-1 and C-2 was reduced, and C-2 (δ C 68.9) and C-1(δ C 48.9) and the HMBC correlations of OH-2 with C-2, C-1 and C-3, and OH-11 with C-11, C-12 and C-9 indicate that C-2 and C-11 (δ C65.2) each connected to a hydroxyl unit, and the planar structure of 11 was determined. Through NOESY spectrum, the correlation between H-2 and H3-20, H3-20 and H3-17 indicated that these protons were in the same plane, and the correlation between H-5 and H-9 indicated that these protons were in opposite planes. Based on ECD data and biogenic pathway, the absolute configuration of compound 11 was determined to be 2R, 5R, 8R, 9R, 10R, 11R, 14S.
[0083] Compound 12 was a light pink solid. According to HR-ESI-MS (m / z 495.2359 [M+Na] + ), combined with NMR data, the molecular formula of compound 12 was determined to be C 27 H 36 O7, the molecular unsaturation is 10. 1 H NMR, 13 The C NMR and HSQC spectra showed seven methyl groups, three methylene groups, six methine groups (including one olefin and three oxygen groups), and eleven non-protonated carbon groups (including two carbonyl groups and five olefins). Its NMR data were similar to those of compound 11. 1 H- 1 The COSY correlations between OH-1 and H-1, OH-3 and H-3, and the HMBC correlations between OH-1 to C-2, and OH-3 to C-2 were observed in the HCOSY spectrum, indicating that C-2 (δ C 210.6) is connected to a keto group, C-1(δ C 82.0) and C-3(δ C 80.4) each connected to a hydroxyl unit, and the planar structure of compound 12 was determined. The correlation between H3-20 and H3-17 in the NOESY spectrum indicates that these protons are in the same plane, and the correlation between H-3 and H-1, H-1 and H-5, and H-5 and H-9 indicates that these protons are in opposite planes. Based on ECD data and biogenic pathways, the absolute configuration of compound 12 is inferred to be 1S, 3R, 5R, 8R, 9S, 10R, 11S, 14S.
[0084] Compound 13 was a white solid. According to HR-ESI-MS (m / z 477.2253 [M+Na] + ), combined with NMR data, the molecular formula of compound 13 was determined to be C 27 H 34 O6, the molecular unsaturation is 11. 1 H NMR, 13 C NMR and HSQC spectra showed seven methyl groups, four methylene groups, four methine groups (one olefin and one oxygen-containing group), and twelve unprotonated carbon groups (three carbonyl groups and five olefin groups). Its NMR data were similar to those of compound 9. 1H- 1 In the H COSY spectrum, COSY correlations between H-1 and H2-2 and HMBC correlations between OH-1 and C-1, C-2, and C-10 were observed, indicating that C-1 (δ C 77.9) and C-2(δ C 42.9) was reduced and C-1 was connected to a hydroxyl group, confirming the planar structure of 13. In the NOESY spectrum, the correlation between H3-20 and H3-17 indicated that these protons were in the same plane, and the correlation between H-1 and H-9, and H-9 and H-5 indicated that these protons were in opposite planes. Based on the ECD data and the biogenic pathway, the absolute configuration of compound 13 was inferred to be 1S, 5R, 8R, 9S, 10R, 14S.
[0085] The hydrogen and carbon NMR data of the above 13 new structural compounds are shown in Tables 1 to 4 respectively.
[0086] Table 1 Compounds 1-6 1 HNMR data (DMSO-d6 at 600MHz) (δin ppm, Jin Hz in Parentheses)
[0087]
[0088]
[0089] Table 2 Compounds 1-8 13 C NMR data (DMSO-d6 at 150MHz)
[0090]
[0091]
[0092]
[0093] Table 3 Compounds 7-11 1 HNMR data (600MHz, δinppm, Jin Hz in Parentheses))
[0094]
[0095]
[0096]
[0097] a Measured in DMSO-d6
[0098] b Measured in CDCl3
[0099] Table 4 Compounds 9-13 13 C NMR data (150MHz)
[0100] no. <![CDATA[9 a ]]> <![CDATA[10 a ]]> <![CDATA[11 b ]]> <![CDATA[12 a ]]> <![CDATA[13 a ]]> 1 160.8,CH 158.3,CH <![CDATA[48.9,CH2]]> 82.0,CH 77.9,CH 2 125.0,CH 127.0,CH 68.9,CH 210.6,C <![CDATA[42.9,CH2]]> 3 203.7,C 204.0,C 216.5,C 80.4,CH 215.4,C 4 44.5,C 49.8,C 47.5,C 45.0,C 46.6,C 5 52.1,CH 44.4,C 58.1,CH 51.3,CH 49.2,CH 6 <![CDATA[17.7,CH2]]> <![CDATA[17.9,CH2]]> <![CDATA[19.1,CH2]]> <![CDATA[18.1,CH2]]> <![CDATA[18.4,CH2]]> 7 <![CDATA[31.2,CH2]]> <![CDATA[31.3,CH2]]> <![CDATA[32.5,CH2]]> <![CDATA[31.3,CH2]]> <![CDATA[30.6,CH2]]> 8 45.0,C 41.5,C 40.6,C 40.9,C 45.4,C 9 55.0,CH 42.3,CH 50.7,CH 51.1,CH 61.1,CH 10 38.4,C 38.6,C 38.5,C 49.7,C 42.1,C 11 198.1,C <![CDATA[22.7,CH2]]> 65.2,CH 66.1,CH 202.3,C 12 129.1,CH 128.3,CH 129.4,CH 130.9,CH 129.2,CH 13 152.2,C 131.8,C 133.8,C 131.9,C 154.1.C 14 97.3,C 99.4,C 99.1,C 99.3,C 97.0,C 15 <![CDATA[29.5,CH2]]> <![CDATA[28.5,CH2]]> <![CDATA[29.4,CH2]]> <![CDATA[29.5,CH2]]> <![CDATA[29.7,CH2]]> 16 <![CDATA[18.7,CH3]]> <![CDATA[18.4,CH3]]> <![CDATA[18.9,CH3]]> <![CDATA[18.7,CH3]]> <![CDATA[18.8,CH3]]> 17 <![CDATA[19.6,CH3]]> <![CDATA[16.3,CH3]]> <![CDATA[19.8,CH3]]> <![CDATA[18.5,CH3]]> <![CDATA[18.9,CH3]]> 18 <![CDATA[27.9,CH3]]> <![CDATA[67.1,CH3]]> <![CDATA[25.1,CH3]]> <![CDATA[28.9,CH3]]> <![CDATA[28.5,CH3]]> 19 <![CDATA[21.8,CH3]]> <![CDATA[17.7,CH2]]> <![CDATA[21.8,CH3]]> <![CDATA[16.8,CH3]]> <![CDATA[20.0,CH3]]> 20 <![CDATA[20.3,CH3]]> <![CDATA[20.4,CH3]]> <![CDATA[18.4,CH3]]> <![CDATA[15.1,CH3]]> <![CDATA[13.1,CH3]]> 1′ 160.5,C 160.8,C 161.5,C 160.7,C 160.5,C 2′ 99.4,C 99.0,C 99.5,C 98.9,C 99.4,C 3′ 170.3,C 170.7,C 171.0,C 170.9,C 170.3,C 4′ 102.7,C 102.6,C 102.9,C 102.6,C 102.8,C 5′ 161.6,C 160.9,C 160.7,C 161.0,C 161.6,C 6′ <![CDATA[17.4,CH3]]> <![CDATA[17.3,CH3]]> <![CDATA[17.2,CH3]]> <![CDATA[17.4,CH3]]> <![CDATA[17.4,CH3]]> 7′ <![CDATA[9.8,CH3]]> <![CDATA[9.8,CH3]]> <![CDATA[9.7,CH3]]> <![CDATA[9.8,CH3]]> <![CDATA[9.8,CH3]]>
[0101] a Measured in DMSO-d6b Measured in CDCl3
[0102] Example 2: Evaluation of the anti-inflammatory activity of Breviane spirocyclic diterpenoids
[0103] (1) Cultivation of macrophage RAW264.7 cells: Logarithmically growing cells were inoculated into 96-well plates (1×10 5 Each test sample was set up with 3 replicates. The cells were cultured in a biochemical incubator at 37°C with 5% CO2 for 24 h.
[0104] (2) Addition of test compound: After the test compound was dissolved in DMSO, it was diluted with culture medium to a certain concentration and added to a 96-well plate. The experiment set up a control group, a model group (1 μg / mL LPS stimulation), a positive control group (1 μg / mL LPS stimulation + 10 μM BAY11-7085) and a test compound group (1 μg / mL LPS stimulation + 50 μM test compound).
[0105] (3) After adding the test compound, the cells were cultured in a biochemical incubator at 37°C containing 5% CO2 for 24 h. The supernatant in each well was then collected and the NO content was tested according to the following steps.
[0106] (4) Determination of NO content: dilute the nitrite standard solution in the kit to 50, 25, 12.5, 6.25, and 3.125 μM. According to the experimental dosage, mix equal volumes of reagent A and reagent B to prepare the Griess reagent. Reagent A (1 mg / mL N-1-naphthylethylenediamine hydrochloride solution). Reagent B (10 mg / mL sulfanilic acid solution). Take 75 μL of the nitrite standard solution or the compound to be tested and add it to a 96-well plate. Add 10 μL of Griess reagent and 65 μL of deionized water to each well, shake the solution to mix, react at room temperature for 30 minutes, and then test the absorbance of the reaction solution at 548 nm. OD 548 The concentration of the compound to be tested is calculated by the standard curve method.
[0107] The results of anti-inflammatory activity evaluation showed that compounds 5 and 7 had significant anti-inflammatory activity, and their IC 50The values were 1.40 and 5.34 μM, respectively. In particular, compound 5 has strong anti-inflammatory activity and can be used for the development of anti-inflammatory drugs. Therefore, the present invention provides candidate compounds for the development of anti-inflammatory drugs and provides a scientific basis for the development and utilization of deep-sea natural products.
[0108] Example 3: Evaluation of Breviane spirocyclic diterpenoids' anti-novel coronavirus pseudovirus activity
[0109] The inhibitory effect of mixed terpenoid compounds on the new coronavirus was evaluated by using the SARS-CoV-2omicron subvariant BA.2 pseudovirus-infected 293T-ACE2 cell model. The reporter gene luciferase was inserted into the model, and the Lucifer value was measured to indicate the level of viral replication. First, a pseudovirus was prepared and the viral lucifer value was measured. The specific steps are as follows: (1) Preparation of pseudovirus
[0110] a) 293T cells were plated in 10 cm plates in advance, 2×10 6 Cells were cultured for 12-16h.
[0111] b) Use sterile PBS to dilute the transfection reagent vigofect (Vigorax Biotech) to 500 μL. Use the same PBS to dilute 10 μg of pcDNA3.1-spike-BA.2 plasmid and 10 μg of HIV-1 backbone plasmid pNL4-3-luc-RE to 500 μL. Mix the plasmid and transfection reagent to the same volume, let it stand for 15 min, and evenly add it to the cells.
[0112] c) 6 h after transfection, the culture medium was discarded, 10 mL of DMEM medium containing 10% FBS was added to the cells, and the cells were cultured for another 48 h.
[0113] d) Collect the supernatant, and spin at 3600 rpm / min for 6 min. Filter the pseudovirus supernatant through a 0.45 μM filter membrane and freeze it in a -80°C refrigerator for later use.
[0114] e) The collected pseudovirus was diluted 5-fold to infect 293T-ACE2 cells, and fresh DMEM medium was replaced after 10 hours to continue culturing for 48 hours.
[0115] f) Use 1× cell lysis buffer (Promega) to lyse the cells and transfer them to an opaque white plate, detect the Lucifer value, analyze the relative fluorescence value of the virus, and calculate the number of viruses used in the neutralization experiment.
[0116] (2) Evaluation of the anti-SARS-CoV-2 pseudovirus activity of the test compounds
[0117] a) 293T-ACE2 cells were plated in 96-well plates in advance, with 30,000 cells per well. After culturing for 12-16 hours, the cell density was approximately 90%.
[0118] b) Compounds were diluted 3-fold starting from 50 μM in serum-free DMEM medium (three replicate wells for each concentration).
[0119] c) Dilute the SARS-CoV-2 pseudovirus with serum-free DMEM at a ratio of 1:3, mix the diluted compound and virus in equal volumes to make a total of 100 μL, incubate at 37°C for 1 h, add the mixture to the plated cells, infect for 10 h, replace the DMEM medium with 10% FBS, and continue culturing in the incubator for 48 h.
[0120] d) Cells were lysed using 1× cell lysis buffer (Promega) and transferred to an opaque white plate. Lucifer values were detected, fluorescence values were analyzed, and the infection rate of cells in each well was counted. Graphpad 10.0 software was used to analyze the data and calculate the IC of the compound. 50 .
[0121] The results of antiviral activity evaluation showed that Breviane spirocyclic diterpenoid compounds 5 and 9 had significant inhibitory activity against SARS-CoV-2omicron subvariant BA.2 pseudovirus, and their IC 50 The values are 8.47 and 10.25 μM, respectively. It can be used for the research and development of anti-new coronavirus drugs. Therefore, the present invention provides candidate compounds for the research and development of anti-new coronavirus drugs and provides a scientific basis for the development and utilization of deep-sea natural products.
[0122] The method of the present invention has been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein within the content, spirit and scope of the present invention to implement and apply the technology of the present invention. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention.
Claims
1. A Breviane spirocyclic diterpenoid compound having one of the following structures or its stereoisomers, tautomers, nitrogen oxides, solvates, metabolites, pharmaceutically acceptable salts, prodrugs or isotope labels:
2. A pharmaceutical composition comprising the Breviane spirocyclic diterpenoid compound according to claim 1 and pharmaceutical excipients.
3. The pharmaceutical composition according to claim 2, characterized in that It also includes other effective ingredients; the other effective ingredients are traditional Chinese medicine ingredients and / or western medicine ingredients.
4. The pharmaceutical composition according to claim 3, characterized in that The western medicine ingredients include: at least one of apimod, R82913, DS-6930, ONO 5334, oseltamivir phosphate, tetrandrine, clofazimine, astemizole, recombinant human angiotensin-converting enzyme 2 or favipiravir and / or pharmaceutically acceptable salts thereof.
5. Use of the Breviane spirocyclic diterpenoid compound according to claim 1 or the pharmaceutical composition according to any one of claims 2-4 in the preparation of a medicament for preventing or treating inflammation or diseases related to novel coronavirus infection.
6. The use according to claim 5, characterized in that The new coronavirus is SARS-CoV-2omicron subvariant BA.
2.
7. The use according to claim 5, characterized in that In the use of a drug for treating inflammation-related diseases, the compound or the compound contained in the pharmaceutical composition is compound 5 or a salt thereof, or compound 7 or a salt thereof; 8. The use according to any one of claims 5 to 6, characterized in that: In the use of medicine for treating COVID-19-related diseases, the compound or the compound contained in the composition is compound 5 or a salt thereof, or compound 9 or a salt thereof; 9. A method for preparing and extracting the Breviane spirocyclic diterpenoid compound according to claim 1, comprising: (1) using an organic solvent to ultrasonically extract the fermentation product of deep-sea fungus Penicillium chrysogenum F59 to obtain an organic extract; the organic solvent is selected from one or more combinations of ethyl acetate, dichloromethane, n-butanol, acetone, and methanol; (2) separating the organic extract in step (1) by normal phase silica gel column chromatography, using a dichloromethane-methanol gradient elution system with a volume ratio of 1:0 to 0:1; obtaining five fractions Fr.1, Fr.2, Fr.3, Fr4, and Fr5; (3) passing the fraction Fr.3 obtained in step (2) through a reverse ODS silica gel column and eluting with a methanol / water gradient with a methanol ratio ranging from 75% to 100%, to obtain seven subfractions, namely, Fr.3-1, Fr.3-2, Fr.3-3, Fr.3-4, Fr.3-5, Fr.3-6, and Fr.3-7; (4) passing the subfraction Fr.3-2 in step (3) through a normal phase silica gel column, using petroleum ether / ethyl acetate isocratic elution, volume ratio of 15:1; then separating and purifying by semi-preparative high pressure liquid chromatography, using acetonitrile / water, volume ratio of 32:68 as eluent, to prepare compounds 3 and 12; (5) The subfraction Fr.3-6 in step (3) was subjected to normal phase silica gel column chromatography using isocratic elution with dichloromethane / methanol in a volume ratio of 50:1; and then separated and purified by semi-preparative high pressure liquid chromatography using acetonitrile / water in a volume ratio of 45:55 as the eluent to prepare compound 11; (6) The fraction Fr.4 obtained in step (2) was subjected to normal phase silica gel column chromatography, eluted isocratically with dichloromethane / methanol, with a volume ratio of 100:1, to obtain five sub-fractions, Fr.4-1, Fr.4-2, Fr.4-3, Fr.4-4, and Fr.4-5; (7) The subfraction Fr.4-1 in step (6) was separated and purified by isocratic elution with petroleum ether / ethyl acetate on a normal phase silica gel column, with a volume ratio of 10:1, and semi-preparative high pressure liquid chromatography, with an eluent of acetonitrile / water, with a volume ratio of 33:67, to obtain compound 1; (8) The subfraction Fr.4-2 in step (6) was subjected to Sephadex LH-20 gel column chromatography, eluted with methanol, and then separated and purified by semi-preparative high pressure liquid chromatography to prepare compound 5, compound 8, and compound 10; (9) The subfraction Fr.4-3 in step (6) was separated and purified by isocratic elution with dichloromethane / methanol (volume ratio: 50:1) on a normal phase silica gel column and semi-preparative high pressure liquid chromatography (eluent: acetonitrile / water (volume ratio: 33:67) to obtain compounds 7 and 13; (10) The subfraction Fr.4-4 in step (6) was separated and purified by isocratic elution with dichloromethane / methanol (volume ratio 40:1) on a normal phase silica gel column and semi-preparative high pressure liquid chromatography (eluent acetonitrile / water (volume ratio 40:60) to obtain compounds 4 and 9; (11) The subfraction Fr.4-5 in step (6) was separated and purified by isocratic elution with dichloromethane / methanol in a normal phase silica gel column, with a volume ratio of 30:1, and semi-preparative high pressure liquid chromatography, with acetonitrile / water in a volume ratio of 45:55 as the eluent, to obtain compounds 2 and 6.
10. The method according to claim 9, characterized in that The fermentation method of the deep-sea fungus Penicillium chrysogenum F59 fermentation product comprises: (1) Deep-sea fungus Penicillium chrysogenum F59 was transferred to sterilized PDB medium and cultured in a shaker to obtain the seed fermentation liquid of the fungus; (2) The prepared seed culture solution is inoculated into a rice solid culture medium and placed in a constant temperature chamber at 20-30° C. for static fermentation culture for 25-35 days.
Citation Information
Patent Citations
Diterpenoid compound and application thereof in preparation of antitumor drugs
CN108947790A
Di-sesquiterpene compound derived from marine fungi, preparation method of di-sesquiterpene compound and application of di-sesquiterpene compound in preparation of anti-inflammatory drugs
CN109970538A
Preparation method and application of diterpenoid compound
CN118459475A
